Key Details
Price
$87.81Last Dividend
$0.52Annual Revenue
$33.72 BAnnual EPS
$2.70Annual ROE
87.29%Beta
0.73Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 02, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Aug 16, 2024Next split:
N/ARecent split:
Sept 20, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.
Novo Nordisk (NVO) has recently caught the attention of Zacks.com users. Therefore, it's important to look into what the future holds for this stock.
Novo Nordisk is expected to achieve a 24% compound annual growth rate over the next two years, thanks to strong growth in the obesity drug market and better operational efficiency, with an intrinsic value suggesting a 29% safety margin. Although there is competition from Eli Lilly and some short-term production challenges, Novo Nordisk maintains a solid position in a rapidly growing industry, and its price-to-earnings ratios are likely to increase. My valuation model estimates a price target of $134.60 for December 2026, indicating a Strong Buy with considerable upside potential, and I plan to allocate 17.5% of my portfolio to it.
In the latest trading session, Novo Nordisk (NVO) finished at $85.73, showing a decrease of 1.88% compared to the day before.
Novo Nordisk's Ozempic is the most well-known weight-loss medication, but there are other successful drugs in this category as well. Recently, Elon Musk shared his weight loss by dressing as Santa Claus on X, referring to himself as "Ozempic Santa," but he wasn't actually using Ozempic.
Ozempic has gained immense popularity as a weight loss drug, generating nearly $14 billion in sales in 2023 for its manufacturer, Novo Nordisk A/S, which is now Europe's most valuable company. Originally developed for diabetes treatment, Ozempic's weight loss benefits have become a lucrative side effect, although the company faces numerous legal challenges and regulatory scrutiny. Looking ahead, Novo Nordisk is investing heavily in new obesity treatments and expanding into markets like China, with expectations that the obesity drug market will reach $100 billion by 2030.
In the competition to create the next popular weight loss medication, Novo Nordisk's stock fell by 19% on December 20. This drop occurred after the company announced results from a late-stage clinical trial, which it described as a success.
Ozempic has gained immense popularity as a weight loss drug, generating nearly $14 billion in sales in 2023 for its manufacturer, Novo Nordisk A/S, which is now Europe's most valuable company. Originally developed for diabetes treatment, Ozempic's weight loss benefits have become a lucrative side effect, although the company faces numerous legal challenges and regulatory scrutiny. Looking ahead, Novo Nordisk is investing heavily in new obesity treatments and expanding into markets like China, with expectations that the obesity drug market could reach $100 billion by 2030.
In the most recent trading session, Novo Nordisk (NVO) finished at $87.37, which is a decrease of 1.51% compared to the day before.
Novo Nordisk's latest CagriSema study did not meet expectations, causing a significant drop in its stock as investors grew more negative. While Eli Lilly's stock has been performing better, it is unlikely that Novo Nordisk will give up its leading position in the market anytime soon. The company still has various chances to broaden the uses of its weight loss medications and possibly increase its total addressable market.
FAQ
- What is the primary business of Novo Nordisk A/S?
- What is the ticker symbol for Novo Nordisk A/S?
- Does Novo Nordisk A/S pay dividends?
- What sector is Novo Nordisk A/S in?
- What industry is Novo Nordisk A/S in?
- What country is Novo Nordisk A/S based in?
- When did Novo Nordisk A/S go public?
- Is Novo Nordisk A/S in the S&P 500?
- Is Novo Nordisk A/S in the NASDAQ 100?
- Is Novo Nordisk A/S in the Dow Jones?
- When was Novo Nordisk A/S's last earnings report?
- When does Novo Nordisk A/S report earnings?